Nanobiotix S.A.(NBTX), a late-stage clinical biotechnology company, announced on Monday preclinical data for the Nanoprimer platform in sequence with lipid nanoparticle-delivered recombinant DNA, at the annual meeting of the American Association for Cancer Research (AACR).
The lipid nanoparticle-delivered recombinant DNA (LNP-DNA) therapies previously developed caused rapid hepatic clearance via the mononuclear phagocytic system (MPS), limiting systemic bioavailability and increasing hepatic toxicity.
The company's proprietary Nanoprimer is an early-stage nanotherapeutic platform, developed to increase drug bioavailability and decrease unintended off-target effects in the liver to improve patient outcomes.
When administered intravenously in mouse models with LNP-DNA, it occupied hepatic clearance pathways like MPS to increase bioavailability and target accumulation. This resulted in a reduced hepatic uptake and toxicity, increased circulating levels of LNP-DNA, and mitigated the inflammatory response.
The positive preclinical results indicate that the Nanoprimer has potential broad applications in LNP-DNA formulations, as well as for the delivery of RNA, gene therapies and advanced biologics.
NBTX closed Friday at $33.79, up 4.10%
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.